Mesoblast looks to exclude some investors from shareholder class action

Class Actions 2023-01-25 1:54 pm By Cindy Cameronne | Sydney

Please login to bookmark

Regenerative medicine company Mesoblast has hit back at a shareholder class action over its Remestemcel-L treatment for COVID-19, saying that some group members are barred from bringing claims because of a settlement reached in a US class action.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au